Enliven: Mizuho price target hike on positive ELVN-001 Phase 1b CML data

 Mizuho Securities raised its price target on Enliven Therapeutics to $45 from $41 while maintaining an Outperform rating, citing the company’s recent Phase 1b data for ELVN-001 in chronic myeloid leukemia (CML) and describing it as an under-rated asset in the space. The upgrade, reported on March 24, 2026, highlights the drug candidate’s promising results—including a 69% cumulative major molecular response (MMR) rate by 24 weeks in certain cohorts and 35% achieving deep molecular response—along with plans to initiate the registrational ENABLE-2 Phase 3 trial in the second half of 2026 after FDA alignment on dose and design. Additional Phase 1 data is expected mid-year. This development builds on earlier 2026 momentum from the initial Phase 1b readout, strong cash position, and analyst optimism, prompting buying interest in premarket trading on March 25 and resulting in the 15.51% gain. The stock had closed near recent highs the prior day, reflecting ongoing positive sentiment around the CML program

https://finviz.com/quote.ashx?t=ELVN&p=d